Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial

E. Capelletto, M.R. Migliorino, A. Morabito, R. Chiari, F. Grossi, M. Tiseo, F.D. Costanzo, A. Delmonte, G. Romano, D. Galetta, V. Scotti, V. Gregorc, S. Pisconti, G.L. Ceresoli, A.D. Conte, L. Ciuffreda, I. Colantonio, E. Bria, S. Ricciardi, A. ManzoG. Metro, A.M. Morelli, R. Critelli, M.V. Pacchiana, I. Stura, G. Migliaretti, S. Novello

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)210-217
Number of pages8
JournalLung Cancer
Volume134
DOIs
Publication statusPublished - 2019

Keywords

  • Docetaxel
  • Nintedanib
  • Non-small cell lung cancer
  • Quality of life
  • Toxicity
  • alanine aminotransferase
  • aspartate aminotransferase
  • docetaxel
  • gamma glutamyltransferase
  • nintedanib
  • adult
  • afebrile neutropenia
  • aged
  • allergic reaction
  • alopecia
  • anemia
  • arterial thromboembolism
  • Article
  • cancer control
  • cancer patient
  • cancer recurrence
  • cancer staging
  • clinical feature
  • cohort analysis
  • controlled clinical trial
  • controlled study
  • coughing
  • diarrhea
  • digestive system perforation
  • drug dose reduction
  • drug efficacy
  • drug safety
  • drug tolerability
  • drug withdrawal
  • dyspnea
  • fatigue
  • female
  • fever
  • follow up
  • human
  • hypersensitivity
  • hypertension
  • hypertransaminasemia
  • leukocyte count
  • leukopenia
  • maintenance chemotherapy
  • major clinical study
  • male
  • multiple cycle treatment
  • nail disease
  • nausea
  • neutropenia
  • non small cell lung cancer
  • open study
  • oral mucositis
  • outcome assessment
  • overall survival
  • pain
  • paresthesia
  • phase 2 clinical trial
  • priority journal
  • progression free survival
  • quality of life
  • respiratory tract hemorrhage
  • side effect
  • skin toxicity
  • survival time
  • thrombocytopenia
  • vein thrombosis
  • vomiting

Cite this

Capelletto, E., Migliorino, M. R., Morabito, A., Chiari, R., Grossi, F., Tiseo, M., Costanzo, F. D., Delmonte, A., Romano, G., Galetta, D., Scotti, V., Gregorc, V., Pisconti, S., Ceresoli, G. L., Conte, A. D., Ciuffreda, L., Colantonio, I., Bria, E., Ricciardi, S., ... Novello, S. (2019). Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial. Lung Cancer, 134, 210-217. https://doi.org/10.1016/j.lungcan.2019.06.028